Antimicrobial resistance (AMR) poses a global health challenge, particularly in maritime environments where unique conditions foster its emergence and spread. Characterized by confined spaces, high population density, and extensive global mobility, ships create a setting ripe for the development and dissemination of resistant pathogens. This review aims to analyse the contributing factors, epidemiological challenges, mitigation strategies specific to AMR on ships and to propose future research directions, bridging a significant gap in the literature. Maritime environments facilitate the propagation of AMR through interconnected factors. The confined and communal nature of ships allows resistant pathogens to spread rapidly among diverse populations. The inappropriate and often empirical use of broad-spectrum antibiotics, compounded by limited access to diagnostic tools, accelerates the selection of resistant strains. Poor infection control practices, including inadequate sanitation and ineffective isolation measures, exacerbate the risks. Environmental contamination through untreated wastewater and ballast water discharge introduces resistant bacteria and genes into marine ecosystems, posing additional public health and ecological threats. Surveillance of AMR on ships is hampered by logistical barriers, including the lack of standardized protocols and reporting systems. Documented outbreaks of resistant pathogens, such as methicillin-resistant Staphylococcus aureus, underline the public health risks associated with AMR in maritime settings, alongside significant operational disruptions and environmental impacts. Despite advancements in portable diagnostic technologies, their adoption on ships remains minimal, leaving critical gaps in detection and management. Effective management of AMR in maritime settings necessitates the integration of stewardship programs tailored to shipboard environments, reinforced infection control measures, and advanced wastewater treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.idnow.2025.105027 | DOI Listing |
Microb Genom
January 2025
Leibniz Institute DSMZ - German Collection of Microorganisms and Cell Cultures, Microbial Genome Research, Braunschweig, Germany.
Genomic data on from the African continent are currently lacking, resulting in the region being under-represented in global analyses of infection (CDI) epidemiology. For the first time in Nigeria, we utilized whole-genome sequencing and phylogenetic tools to compare isolates from diarrhoeic human patients (=142), livestock (=38), poultry manure (=5) and dogs (=9) in the same geographic area (Makurdi, north-central Nigeria) and relate them to the global population. In addition, selected isolates were tested for antimicrobial susceptibility (=33) and characterized by PCR ribotyping (=53).
View Article and Find Full Text PDFChem Commun (Camb)
January 2025
Beijing Life Science Academy, Beijing 102206, China.
Detection of low-abundance mutations for the early discovery of fungicide-resistant fungal pathogens is highly demanded, but remains challenging. Herein, we developed a dual-recognition strategy, termed PARPA, involving s Argonaute (pfAgo)-mediated elimination of wild-type fungal genes and CRISPR/Cas12a-based amplicon recognition. This assay can detect fungicide-resistant at relative abundances as low as 0.
View Article and Find Full Text PDFDiscov Nano
January 2025
Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Some of the most crucial turning points in the treatment strategies for some major infectious diseases including AIDS, malaria, and TB, have been reached with the introduction of antimicrobials and vaccines. Drug resistance and poor effectiveness are key limitations that need to be overcome. Conventional liposomes have been explored as a delivery system for infectious diseases bioactives to treat infectious diseases to provide an efficient approach to maximize the therapeutic outcomes, drug stability, targetability, to reduce the side-effects of antimicrobials, and enhance vaccine performance where necessary.
View Article and Find Full Text PDFMol Biol Rep
January 2025
Department of Pharmaceutical Control, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Background: Pseudomonas aeruginosa's inherent and adapted resistance makes this pathogen a serious problem for antimicrobial treatments. Furthermore, its biofilm formation ability is the most critical armor against antimicrobial therapy, and the virulence factors, on the other hand, contribute to fatal infection and other recalcitrant phenotypic characteristics. These capabilities are harmonized through cell-cell communication called Quorum Sensing (QS), which results in gene expression regulation via three major interconnected circuits: las, rhl, and pqs system.
View Article and Find Full Text PDFInfection
January 2025
Department of Thoracic Surgery, Saarland University, 66421, Homburg/Saar, Germany.
Background: Lung transplantation is the ultimate treatment option for patients with advanced cystic fibrosis. Chronic colonization of these recipients with multidrug-resistant (MDR) pathogens may constitute a risk factor for an adverse outcome. We sought to analyze whether colonization with MDR pathogens, as outlined in the German classification of multiresistant Gram-negative bacteria (MRGN), was associated with the success of lung transplantation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!